Mesoblast Limited (MESO)
MESO trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), period ending 2025-06-30, https://www.sec.gov/Archives/edgar/data/1345099/000134509925000067/0001345099-25-000067-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), period ending 2025-06-30.
Profile
| Field | Value |
|---|---|
| Ticker | MESO on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | Australia |
| IPO year | 2015 |
| SEC CIK | 0001345099 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | C3 |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $17.2M |
| Net income | -$102.1M |
| Operating income | Not in SEC XBRL data |
| Net margin | -593.9% |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | Not in SEC XBRL data |
| Total assets | Not in SEC XBRL data |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 105.1× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document PROSPECTUS | 424B3 | 2026-01-14 |
| Latest annual report | 20-F | 2026-08-27 |
| Latest quarterly / interim | 6-K | 2026-10-13 |
Source: SEC EDGAR submissions feed, 594 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -1.5% |
| 1 month | -6.9% |
| 3 months | -23.1% |
| Year to date | -23.9% |
| 1 year | -24.3% |
| From 52-week high | -34.5% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| VIR | Vir Biotechnology Inc. | $10.61 | -6.11% | $1.8B |
| RXRX | Recursion Pharmaceuticals Inc. | $3.83 | -4.36% | $2.1B |
| BCRX | BioCryst Pharmaceuticals Inc. | $8.07 | -3.47% | $2.1B |
| VCEL | Vericel Corporation | $40.30 | -0.79% | $2.1B |
| ALVO | Alvotech | $5.38 | -2.18% | $2.1B |
| NVAX | Novavax Inc. | $12.82 | +1.26% | $2.1B |
| MAZE | Maze Therapeutics Inc. | $26.66 | -3.75% | $1.5B |
| IMCR | Immunocore Holdings plc | $27.82 | -4.20% | $1.4B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier